Literature DB >> 3677571

Phenytoin-induced hypersensitivity reactions.

T R Prosser1, R D Lander.   

Abstract

A case of phenytoin-induced hepatitis with mononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed. A 23-year-old black woman with a two-month history of seizure disorder was admitted to a hospital with nausea, vomiting, fever, lymphadenopathy, diffuse maculopapular rash, left-upper-quadrant tenderness, and hepatomegaly. She was receiving phenytoin sodium 300 mg/day; carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia. Phenytoin was discontinued after admission; however, phenytoin 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and pruritus developed. Over the next few days, signs and symptoms of hepatotoxicity progressed, and she became comatose. Seizures were treated with diazepam. She began to recover after 10 days of supportive therapy and was discharged several weeks later on primidone therapy. Serious phenytoin hypersensitivity reactions may appear as dermatologic, lymphoid, or hepatic syndromes. Fever, rash, and lymphadenopathy often accompany hepatic injury. Encephalopathy and death may occur. Proposed mechanisms for phenytoin hypersensitivity include antigen-antibody reactions, alteration of lymphocyte function, and an enzyme abnormality causing the production of toxic metabolites. Treatment is supportive; phenobarbital and carbamazepine may be used with caution as alternate anticonvulsant therapy. The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3677571

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  4 in total

Review 1.  Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.

Authors:  S R Knowles; L E Shapiro; N H Shear
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

Review 2.  Immunological adverse effects of anticonvulsants. What is their clinical relevance?

Authors:  F De Ponti; S Lecchini; M Cosentino; C M Castelletti; A Malesci; G M Frigo
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

Review 3.  Antiepileptic hypersensitivity syndrome: clinicians beware and be aware.

Authors:  Olga Bessmertny; Trinh Pham
Journal:  Curr Allergy Asthma Rep       Date:  2002-01       Impact factor: 4.919

4.  Hypersensitivity reaction associated with phenytoin.

Authors:  T H Indu; Roopa Satyanarayan Basutkar
Journal:  J Basic Clin Pharm       Date:  2015-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.